- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04292938
McArdle Disease Treatment by Ketogenic Diet
Ketogenic Diet in McArdle Disease: a Multicentric Single Blind Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
McArdle disease (myophosphorylase deficiency, glycogen storage disease type 5, GSD5, OMIM # 232600) is an inherited metabolic disorder of skeletal muscle. Affected patients suffer from genetically determined lack of the enzyme muscle glycogen phosphorylase, which is essential for glycogen metabolism. The condition is caused by homozygous or compound heterozygous mutations in the muscle glycogen phosphorylase gene (PYGM) located at chromosome 11q13. Many pathogenic mutations have been identified in the gene, which spans 20 exons, and many are population specific. The most common mutation in Northern Europe and North America is a nonsense mutation at Arg50stop (R50X) in exon 1 (previously referred to as R49X). A second frequent mutation in this population, and in Spanish patients, is Gly205Ser (G205S). McArdle disease is a rare disorder with an estimated incidence of 1:100,000.
Complete absence of muscle phosphorylase results in the inability to mobilize muscle glycogen stores, which are normally required as substrate for energy generation during anaerobic metabolism, which occurs during start of exercise and high-intensity efforts. In affected people, symptoms of fatigue and discomfort therefore occur within minutes of initiating any activity and during strenuous activity such as lifting heavy weights or walking uphill. If the activity is continued despite symptoms, a severe cramp (which is called a contracture in GSD5, because the muscle contraction is not caused by neural stimulation) occurs, which leads to muscle damage. If the damage is substantial, acute rhabdomyolysis may occur, which in turn can result in dark brown/black discoloration of urine (myoglobinuria). When rhabdomyolysis is severe, myoglobinuria can lead to acute renal failure, requiring treatment with dialysis.
In patients with GSD5, aerobic metabolism is limited and varies as a function of the availability of alternative fuels as a function of exercise and diet. The second wind phenomenon is illustrative. The phenomenon is characterized by the ability to increase work output after about 7-8 minutes of exercise. The second wind occurs as a consequence of increased availability and metabolism of alternative fuel substrates, preferentially glucose supplied from the liver, but also free fatty acids metabolized through oxidative phosphorylation and ketones produced by the liver. Despite these compensatory fuels, which can substitute for the absent glycogen breakdown in muscle, the capacity for oxidative phosphorylation is impaired in GSD5, because of an almost complete absence of pyruvate, a by-product of glycolysis.
Reduced oxidative phosphorylation in untrained patients with GSD5 in turn reduces oxygen consumption to approximately 35% of normal and there is a disproportionate increase in heart rate during exercise in patients with GSD5 compared with healthy controls. Thus, unconditioned people with GSD5 have very limited exercise capacity, which affects quality of life.
Most patients present in the second or third decade, although symptoms are often reported retrospectively from childhood. With advancing age a 20-25% proportion of patients develop fixed muscle weakness predominantly affecting the shoulder girdle. No clear cut genotype-phenotype correlation has been found to explain the clinical variation in severity observed even within families, but the influence of polymorphisms in other genes has been hypothesized.
Currently, there is no treatment for the condition. There have been a small number of randomized controlled treatment trials, however the largest number of participants in any previous study was 19.
Taking glucose prior to exercise alleviates muscle symptoms by inducing a 'second wind' at the onset of exercise, but has detrimental effects on weight if used too frequently. A Cochrane systematic review of training in GSD5 identified a few non-randomized trials of aerobic training or dietary manipulation either with supplements such as creatine or with shift towards lipid sources, which showed no harmful effect and suggest benefit over a number of months however long-tern results and confirmation on larger cohorts are warranted.
In spite of these indications, controlled training and dietary habits are seldom followed by patients, who experience significant limitations in activity of daily living and restriction in their participation.
A key limitation to exercise in GSD5 is the bottleneck in fuel flow through the Tri Carboxylic Acid (TCA) cycle, which is imposed by the minimal supply of glucosyl units from muscle glycogen and thus glycolytic flux to feed the TCA cycle.
Dietary manipulation has been identified since the eighties as a potential strategy to improve functioning in GSD5. In spite of initial indications for high protein regimens, later experimental comparison of high protein vs high carbohydrate diets indicated a superiority for the latter. Particular interest was also focussed on diets with predominant lipid energy source (ketogenic or low carbohydrate ketogenic LCKD) with the assumption that ketones are easily taken up by mitochondria and can substitute for the missing acyl-CoA moieties not provided by the staggering glycolysis blocked upstream for the inaccessibility of muscle glycogen. LCKD has a long history as a therapeutic strategy for several conditions (epilepsy, PDH defect, GLUT1 defect) with a good record of safety and efficacy and a poorer record of tolerability. Isolated experiences of LCKD have been carried out in GSD5 patients (maximum 4 patients) with promising results.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Treviso
-
Conegliano, Treviso, Italy, 31015
- IRCCS Medea
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- molecularly defined Glycogen storage disease type 5, ability to perform a cycle ergometer exercise test
Exclusion Criteria:
- pregnancy,
- medical condition preventing a LCKD regimen (CPT2 or acyl-CoA deficiency, liver heart or kidney failure, unstable diabetes).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Ketogenic diet
patients will follow a low carbohydrate high lipid personalized diet causing blood BOHB level to be between 1.5-4 mmol/l for six months
|
Dietary modification, including the use of supplements, with the aim of reaching a lipid/carbohydrate-protein 3:1 ratio with a minimum 1g/Kg/die in protein
Other Names:
|
No Intervention: control group
Patients will be asked to maintain their usual dietary regimen
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in maximal (peak) oxidative capacity (VO2max)
Time Frame: six months
|
pre to post diet comparison of maximal O2 consumption attained during an incremental cycle ergometer test
|
six months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
heart rate
Time Frame: six months
|
change in the maximum heart rate during constant load cycling exercise (HR const)
|
six months
|
maximal workload
Time Frame: six months
|
change in maximal workload capacity (Wmax) at incremental cycle ergometer test
|
six months
|
12 min walking test
Time Frame: six months
|
the maximum walking distance in 12 minutes
|
six months
|
Fatigue
Time Frame: six months
|
self-rated severity of fatigue symptoms on a Fatigue Severity Scale (FSS).
The FSS scoring is 1-7 on 9 averaged domains. 1 is minimal fatigue and 7 is maximal.
|
six months
|
Short Form 36 (SF36)
Time Frame: six months
|
the quality of life assessed using the 36-item Short Form Health Survey questionnaire (SF36).
SF36 scoring is 0-100 with higher values indicating worse outcome
|
six months
|
Disability
Time Frame: six months
|
the functional disability assessed using the WHO Disability Assessment Schedule 2.0 (WHODAS 2.0).
WHO-DAS 2.0 scoring is 0-100 with higher scores indicating worse outcome
|
six months
|
exertion
Time Frame: six months
|
the rate of Perceived Exertion during constant workload cycling (RPEconst) scored on a NRS scale 0-10 where 10 is maximum pain
|
six months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Andrea Martinuzzi, MD, PhD, IRCCS E Medea
Publications and helpful links
General Publications
- Quinlivan R, Martinuzzi A, Schoser B. Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V). Cochrane Database Syst Rev. 2014 Nov 12;2014(11):CD003458. doi: 10.1002/14651858.CD003458.pub5.
- Busch V, Gempel K, Hack A, Muller K, Vorgerd M, Lochmuller H, Baumeister FA. Treatment of glycogenosis type V with ketogenic diet. Ann Neurol. 2005 Aug;58(2):341. doi: 10.1002/ana.20565. No abstract available.
- Vorgerd M, Zange J. Treatment of glycogenosys type V (McArdle disease) with creatine and ketogenic diet with clinical scores and with 31P-MRS on working leg muscle. Acta Myol. 2007 Jul;26(1):61-3.
- Cai QY, Zhou ZJ, Luo R, Gan J, Li SP, Mu DZ, Wan CM. Safety and tolerability of the ketogenic diet used for the treatment of refractory childhood epilepsy: a systematic review of published prospective studies. World J Pediatr. 2017 Dec;13(6):528-536. doi: 10.1007/s12519-017-0053-2. Epub 2017 Jul 12.
- Muzykewicz DA, Lyczkowski DA, Memon N, Conant KD, Pfeifer HH, Thiele EA. Efficacy, safety, and tolerability of the low glycemic index treatment in pediatric epilepsy. Epilepsia. 2009 May;50(5):1118-26. doi: 10.1111/j.1528-1167.2008.01959.x. Epub 2009 Feb 12.
- Roehl K, Sewak SL. Practice Paper of the Academy of Nutrition and Dietetics: Classic and Modified Ketogenic Diets for Treatment of Epilepsy. J Acad Nutr Diet. 2017 Aug;117(8):1279-1292. doi: 10.1016/j.jand.2017.06.006.
- Paoli A, Bianco A, Damiani E, Bosco G. Ketogenic diet in neuromuscular and neurodegenerative diseases. Biomed Res Int. 2014;2014:474296. doi: 10.1155/2014/474296. Epub 2014 Jul 3.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 543
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glycogen Storage Disease
-
Duke UniversityKriya TherapeuticsRecruitingGlycogen Storage Disease VI | GLYCOGEN STORAGE DISEASE IXa1 | GLYCOGEN STORAGE DISEASE IXa2 | Glycogen Storage Disease IXB | Glycogen Storage Disease IXC | GSD 9 (All Subtypes) | GSD 6United States
-
University Medical Center GroningenUltragenyx Pharmaceutical IncCompletedGlycogen Storage Disease Type IANetherlands
-
John MitchellCompletedGlycogen Storage Disease Type III | Glycogen Storage Disease Type IA | Glycogen Storage Disease Type IB | Glycogen Storage Disease Type 0Canada
-
CENTOGENE GmbH RostockWithdrawnFructose Metabolism, Inborn Errors | Glycogen Storage Disease Type II | Glycogen Storage Disease | Glycogen Storage Disease Type V | Glycogen Storage Disease Type I | Glycogen Storage Disease Type III | Glycogen Storage Disease Type VII | Glycogen Storage Disease Type IV | Glycogen Storage Disease Type... and other conditionsGermany, India, Sri Lanka
-
Ultragenyx Pharmaceutical IncActive, not recruitingGlycogen Storage Disease Type IAUnited States, Brazil, Canada, Denmark, Germany, Italy, Netherlands, Spain
-
Ultragenyx Pharmaceutical IncCompletedGlycogen Storage Disease Type IANetherlands, United States
-
Ultragenyx Pharmaceutical IncActive, not recruitingGlycogen Storage Disease Type IA | Von Gierke's Disease (GSD Type Ia)Netherlands, United States, Canada, Spain
-
Sanguine BiosciencesTerminatedGlycogen Storage Disease Type IBUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...Recruiting
-
University of ManitobaCo-Investigator - Dr. Cheryl Rockman-GreenbergCompletedHypoglycemia | Glycogen Storage Disorder Type 1 | Cornstarch | GlycosadeCanada
Clinical Trials on Low carbohydrate ketogenic diet
-
Helse Nord-Trøndelag HFUniversity of Oslo; St. Olavs HospitalCompletedObesity, Morbid | LipedemaNorway
-
University of FloridaNot yet recruitingMusculoskeletal Diseases | Aging
-
Duke UniversityRobert C. Atkins FoundationCompleted
-
National University Hospital, SingaporeRecruitingObesity | Overweight | Weight Loss | Ketogenic DietingSingapore
-
CAMC Health SystemCompletedInsulin Resistance | Abdominal Obesity | Systolic Hypertension | Elevated TriglyceridesUnited States
-
National University Hospital, SingaporeEnrolling by invitationObesity | Metabolic Syndrome | Weight Loss | Ketogenic DietingSingapore
-
Robert C. Atkins FoundationCompletedObesity | Overweight | Type 2 Diabetes MellitusUnited States
-
University of California, San FranciscoCompleted
-
University of Roma La SapienzaCompleted